APV102002 was an open-label study comparing a dual-boosted HIV-1 protease inhibitor (PI) [fosamprenavir/lopinavir/ritonavir (FPV/LPV/RTV; 1400 mg/533 mg/133 mg twice daily)] and a high dose of FPV/RTV 1400 mg/100 mg twice daily (HD-FPV/RTV) versus the standard FPV/RTV 700 mg/100 mg twice-daily (STD-FPV/RTV) regimen for 24 weeks.
Introduction
Treatment-emergent resistance against drugs used early in the treatment continuum is the primary factor substantially limiting treatment options in patients with HIV/AIDS, and has been shown to be associated with an increased risk for disease progression and death. 1 Thus, while currently available agents have yielded major improvements in survival for HIV-infected patients initiating combination antiretroviral therapy (ART), 2 new strategies are continually required to address the needs of antiretroviral-resistant individuals. Prior to the availability of new agents specifically developed to target prevalent resistant strains, other clinical strategies were frequently employed, including the use of dual ritonavir (RTV)-boosted protease inhibitors (PIs), as well as the use of increased doses of the individual RTV-boosted PI aimed at increasing drug exposure and achieving an adequate inhibitory quotient. 3, 4 Fosamprenavir (FPV) is the phosphate ester prodrug of amprenavir (APV), and is rapidly and extensively converted to amprenavir in vivo. The combination FPV/RTV has demonstrated antiviral efficacy, durability and tolerability in both oncedaily and twice-daily dosing regimens 5, 6 and, where approved, FPV/RTV is indicated for both ART-naïve and ARTexperienced HIV-1-infected adults. The dosage regimen approved for PI-experienced adults is FPV/RTV 700 mg/100 mg twice daily in combination with other ARTs.
This study (APV102002) was designed to compare the safety and efficacy of a high-dose FPV/RTV 1400 mg/100 mg twicedaily (HD-FPV/RTV) regimen or a dual-boosted HIV-1 PI regimen consisting of FPV/lopinavir (LPV)/RTV 1400 mg/ 533 mg/133 mg twice daily (FPV/LPV/RTV) with those of the standard approved dose of FPV/RTV 700 mg/100 mg twice daily (STD-FPV/RTV) when administered to heavily treatment-experienced patients. The HD-FPV/RTV regimen was selected based on the results of a previous pharmacokinetic study in healthy patients in which this regimen was found to deliver higher plasma amprenavir levels compared with the STD-FPV/RTV regimen, 7 whilst FPV/LPV/RTV was chosen for further evaluation based on previous FPV/LPV/RTV drug interaction studies 8, 9 (where the doses studied herein appeared to deliver the best plasma amprenavir and lopinavir exposures) and in view of previous reports of virological benefit in heavily treatment-experienced patients despite observed reductions in plasma amprenavir and lopinavir concentrations.
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Methods
Population and enrolment criteria
Highly PI-experienced (having experienced virological failure to two or more prior PI-based regimens) male or female HIV-1-infected adult patients who were on a failing (confirmed plasma HIV-1 RNA concentration of 400 copies/mL on treatment and at least 1000 copies/mL at screening) PI-containing regimen and whose viral genotype had at least one primary protease (PRO) mutation other than D30N were recruited. In addition, patients had to be therapy-experienced with the three main antiretroviral classes [nucleo(s/t)ide reverse transcriptase inhibitors (N[t]RTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and PIs], able to understand and comply with protocol requirements and instructions, and provide written informed consent prior to participation in the study. Patients were excluded if their screening virus harboured the I50V mutation, the V32I with I47V mutations or six or more of the following PRO mutations in the screening genotype [APV/RTV Agence Nationale de Recherche sur le SIDA (ANRS) 2004 13 resistance algorithm]: L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S or I84V. The algorithm was later updated in 2006.
14 In addition, patients with virus harbouring 8 of the following PRO mutations in the screening genotype (LPV/RTV mutation score 15 ) were also excluded: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V or L90M. Patients were not permitted to participate if they had medical conditions or required medications that could compromise their safety or interfere with drug absorption, or if they had protocolspecified abnormal laboratory values at screening. There were no exclusion criteria based on CD4-positive T-lymphocyte (CD4) counts.
This study was conducted in accordance with 'good clinical practice', all applicable regulatory requirements and the guiding principles of the Declaration of Helsinki, and was approved by the ethics review boards of each of the investigational centres. Due to recruitment difficulties in the face of novel effective treatment options and practices for highly treatment-experienced patients, the study was terminated prior to reaching the planned sample size of 150 patients. Study closure was based on the last patient recruited reaching the week 24 visit.
Study design and treatments
This study was a Phase III, randomized, controlled, open-label, multicentre trial evaluating the safety and antiviral activity of FPV-based salvage therapy in PI-experienced patients. Recruitment occurred between 25 January 2005 and 6 December 2006, and patients were followed-up until 15 May 2007 at sites in Canada, France, Italy, Germany, Spain and the UK. The study consisted of a screening evaluation, a treatment phase (24 weeks of treatment) and a follow-up evaluation. Patients were assigned (1:1:1) to study treatment in accordance with a central computer-generated randomization schedule. Study site personnel contacted the central randomization service for assignment of a unique identifier (unique treatment number) for each subject participating in the study. Patients were randomized equally into the three treatment arms to receive open-label therapy: standard FPV/RTV 700 mg/100 mg twice daily (STD-FPV/RTV; the control group); high-dose FPV/ RTV 1400 mg/100 mg twice daily (HD-FPV/RTV); or FPV/LPV/ RTV 1400 mg/533 mg/133 mg twice daily. Screening genotyping and virtual phenotyping were conducted to assist optimization of the background antiretroviral agents which had to consist of at least two N(t)RTIs; NNRTIs were not permitted in this study. Substitution of different background ARTs from the same class was permitted throughout the study, and enfuvirtide (T-20) use was allowed. Patients randomized to the STD-FPV/RTV group who met the criteria for virological failure (.5000 copies/mL of plasma HIV-1 RNA following initial suppression to ,400 copies/mL or a plasma HIV-1 RNA decrease from a baseline of ,0.5 log 10 copies/mL at or after week 12) were permitted to switch at or after week 12 to receive either the increased FPV/RTV dose regimen or the FPV/LPV/RTV regimen at the investigator's discretion.
Assessments
Patients were evaluated at day 1 (baseline visit) and at weeks 1, 2, 3, 4, 8, 12, 16, 20 and 24 , and every 8 weeks thereafter. At the baseline visit, CDC classification was assessed, and samples for hepatitis B and C serology, b-human chorionic gonadotropin (where appropriate) and genotypic resistance were collected and analysed. At each visit, samples for HIV-1 RNA, CD4-positive lymphocyte subsets, plasma for pharmacokinetic analysis [trough concentration (C t )], clinical chemistry, fasting lipids and haematology were collected and analysed. Adverse events (AEs) were assessed at each visit; clinical and laboratory AEs were graded according to the 2004 DAIDS (Division of AIDS Clinical Research Policies and Standard Documents) toxicity grading scale.
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Laboratory assays HIV-1 RNA. The Roche COBAS Monitor Amplicor Ultrasensitive PCR Assay Version 1.5 [limit of detection (LOD)¼50 copies/mL] was used; those samples whose PCR results showed .75000 copies/mL of HIV-1 RNA were retested using the Roche COBAS Monitor Amplicor Standard PCR Assay (LOD¼400 copies/mL). Samples with .750000 copies/mL of HIV-1 RNA were diluted and retested to obtain an absolute value.
Pharmacokinetics. Plasma samples were analysed for amprenavir and lopinavir using separate validated high-performance liquid chromatography -tandem mass spectrometric detection assays. The lower limits of quantification for amprenavir and lopinavir concentrations were 10 and 20 ng/mL, respectively, with a higher limit of quantification of 10000 ng/mL for amprenavir and 20000 ng/mL for lopinavir. Concentrations at the end of the dosing interval are reported (C t ).
Genotype and phenotype. Baseline genotype and virtual phenotype drug resistance information was derived using the VircoTYPE Assay version 3.10.0. Interpretation of the virtual phenotype was performed using the VircoTYPE Assay version 4.0.0 clinical cut-offs, as these included cut-offs for the boosted PIs fosamprenavir and atazanavir.
Statistical analysis
The primary objective was to demonstrate the superior efficacy of HD-FPV/RTV and FPV/LPV/RTV over that of STD-FPV/RTV. The primary efficacy analysis was based on the intent-to-treat exposed [ITT(E)] population, which included all patients exposed to at least one dose of randomized study medication. The primary endpoint was the average area under the curve minus baseline (AAUCMB) using a last AAUCMB carried forward analysis strategy. In order to assess the robustness of the results, additional planned sensitivity analyses were conducted, including per-protocol (defined as all randomized patients excluding those with major protocol deviations), discontinuation equals baseline, and last viral load carried forward (LVLCF) analyses. All data following a patient's discontinuation of study medication or switch to an alternative treatment group are discarded and all subsequent data are imputed as described above.
The comparisons were made at week 24 using an analysis of covariance (ANCOVA) adjusting for baseline viral load and enfuvirtide use, and were considered to be statistically significant if the two-sided P value was ,0.025. A Bonferroni multiplicity correction was used to retain an overall type 1 error of 5% for both primary comparisons.
Secondary week 24 efficacy analyses of the proportion of patients with a plasma HIV-1 RNA level of ,400 copies/mL and ,50 copies/mL were performed using the time to loss of virological response (TLOVR) algorithm and were repeated using the missing or discontinuation equals failure (MD¼F) and observed analysis strategies. Assuming a standard deviation (SD) of 0.8 log 10 copies/mL in the AAUCMB of plasma HIV-1 RNA, the original sample size of 150 patients provided 90% power to demonstrate superiority of both the HD-FPV/RTV dose and the FPV/LPV/RTV dose to the STD-FPV/RTV dose at the two-sided 0.025 significance level. A difference between the two treatment groups of 0.6 log 10 copies/mL in the AAUCMB of plasma HIV-1 RNA at week 24 was considered to be clinically meaningful. The final data analysis was planned when all patients had completed at least the week 48 study visit and the data were cleaned and authorized; however, because the study was prematurely discontinued when all enrolled patients had the opportunity to be followed for at least 24 weeks, the final analysis was performed at week 24. The anticipated power of the study with the final sample size of 74 patients was approximately 60%, and thus the interpretation of the treatment comparison results was based on point estimates and confidence intervals (CIs) in addition to P values.
All safety analyses [AEs, deaths and serious adverse events (SAEs)] and clinical laboratory evaluations were performed on the safety population, unless otherwise stated. The safety population included all randomized patients who received at least one dose of the study drug and was analysed by the actual treatment received. For patients switching treatment group, safety and efficacy data were censored at the time of the switch.
Plasma pharmacokinetics samples were included in the analysis of plasma amprenavir and lopinavir C t data if the samples were collected within 8-16 h of dosing. A plasma amprenavir or lopinavir concentration was not considered a C t value if the concentration was 10-fold different from the nearest value observed in that subject; these outlier concentrations were excluded from the analysis. The individual average C t was calculated as the mean of all available C t values for each patient and treatment. Analysis of variance (ANOVA), considering treatment as a fixed effect, was performed using the SAS Mixed Linear Models procedure to compare log-transformed plasma amprenavir C t values between the treatments. The genotypic inhibitory quotient (GIQ) was calculated as the individual average plasma amprenavir C t (ng/mL) divided by the mutation score. The resistance-associated mutations were according to the ANRS 2006 algorithm for FPV/RTV and LPV/RTV. 14, 15 The phenotypic inhibitory quotient (PIQ) was calculated as the individual average plasma amprenavir C t (ng/mL) divided by the baseline amprenavir virtual phenotype.
Summaries of the response for the ,400 copies/mL and/or at least 1.0 log 10 copies/mL below the baseline endpoint by FPV/RTV and LPV/RTV genotypic resistance using the ANRS algorithms, 14, 15 phenotypic clinical cut-offs (CCO), number of NRTI resistance mutations and activity of the background regimen [the number of active agents based on baseline virus phenotypic susceptibility to initial background ART, namely the virtual Phenotypic Sensitivity Score (vPSS)] were presented for the virology population defined as the ITT(E) population excluding patients who discontinued for reasons other than virological failures. The antiviral response for the ,400 copies/mL endpoint by each of the GIQ quartiles and PIQ quartiles was summarized.
This study is registered with ClinicalTrials.gov: identifier NCT00144833.
Results
Study population
A total of 74 highly PI-experienced patients were randomized into the study and received at least one dose of the investigational product ( Figure 1 ). At baseline, the majority of characteristics were well balanced across the three treatment groups ( Table 1 ). The population was predominantly white (92%), with the majority of patients being male (80%). Nineteen patients were co-infected with hepatitis B and/or hepatitis C virus (Table 1) . At baseline, median plasma HIV-1 RNA was 4.59 log 10 copies/mL, median CD4 cell count was 233 cells/mm 3 , 46% of patients had CDC Class C HIV infection, with fewer patients meeting this definition in the STD-FPV/RTV arm. All 74 patients were PI and N(t)RTI experienced and 88% were NNRTI experienced. The median duration of prior PI exposure was 5.8 years, with the majority of patients (68%) experienced with three or more PIs. The median duration of prior N(t)RTI exposure was 9.25 years, with most patients (82%) experienced with four or more N(t)RTIs; the median duration of prior NNRTI exposure was 1.9 years.
Baseline genotype. Baseline PRO and reverse transcriptase (RT) genotypes were consistent with a highly ARTexperienced population, with a median of 11, 9 and 9.5 total PRO mutations and 5, 4 and 4 RT mutations in the STD-FPV/ RTV, HD-FPV/RTV and FPV/LPV/RTV study arms, respectively. Overall, major PRO resistance-associated mutations were most prevalent at residues 46 (55%), 82 (45%) and 90 (61%); the I84V mutation was present in 29% of isolates, with prevalence balanced between the treatment groups. I47A/V was present in ,10% of samples, and the prevalence of V32I was 12%. Using the 2004 ANRS genotypic algorithm 13 which defined the first exclusion criterion of this study, all but one (a major protocol violator) of the patients in the baseline population showed susceptibility to FPV/RTV. However, when the 2006 version 14 (the version current at the time of analysis) was applied retrospectively, only 37% showed susceptibility to FPV/RTV. Overall, 51% of baseline isolates showed genotypic susceptibility to lopinavir, with 63% susceptible baseline isolates in the lopinavir-containing arm. A high proportion of patients in the baseline population (75%) had four or more N(t)RTI resistance-associated mutations, indicating broad class resistance. The main N(t)RTI resistance-associated mutations observed at baseline included M41L (78%), D67N (63%), M184V/I (58%) and T215Y/F (85%). L74V was present in 13 of 59 patients (22%) at baseline. K65R, Y115F and Q151M were present in ,10% of patients (Q151M was present in only one patient in the STD-FPV/RTV group).
Baseline phenotype. Baseline virtual phenotype analysis was consistent with the genotype analysis, particularly when applying the ANRS 2006 algorithm. 14 As shown in Table 1 , a high proportion of patients harboured baseline isolates with intermediate susceptibility (.CCO1 and ,CCO2) to FPV/RTV and LPV/ RTV; only a minority of patients received a background therapy with two or more active drugs (8%, 8% and 2% in the STD-FPV/ RTV, HD-FPV/RTV and FPV/LPV/RTV study arms, respectively), and 80% of patients across arms received a background regimen with no fully active drugs. A total of 12 patients used enfuvirtide; however, of these, only 2, 2 and 1 patient in the STD-FPV/RTV, HD-FPV/RTV and FPV/LPV/RTV study arms, respectively, were enfuvirtide naïve at study entry.
Efficacy
Primary efficacy analysis. At week 24, the total mean decrease in the AAUCMB was 1.01 log 10 copies/mL (SD ¼ 0.952) and was similar across all three treatment groups ( Table 2 ). The estimate of the mean treatment difference adjusted for baseline viral load and enfuvirtide use between the HD-FPV/RTV and STD-FPV/RTV groups was -0.066 (97.5% CI, -0.714, 0.582 and P ¼ 0.816), and was -0.073 (97.5% CI, -0.709, 0.563 and P ¼ 0.794) between the LPV/FPV/RTV and STD-FPV/RTV groups. The AAUCMB results were similar across all prespecified analysis strategies with no evidence of a significant difference between the STD-FPV/RTV group and either the HD-FPV/RTV or FPV/LPV/RTV groups.
Secondary efficacy analyses. In the TLOVR analysis for the ITT(E) population, the proportion of patients achieving ,400 copies/mL of plasma HIV-1 RNA peaked at week 12, with 7/24 (29%), 9/25 (36%) and 8/25 (32%) in the STD-FPV/ RTV, HD-FPV/RTV and FPV/LPV/RTV arms, respectively. After week 16, the overall proportion of responders decreased through to week 24. Overall, response was similar in the three groups, with five patients (21%) in the STD-FPV/RTV group, six patients (24%) in the HD-FPV/RTV group and five patients (20%) in the FPV/LPV/RTV group with ,400 copies/mL of plasma HIV-1 RNA at week 24; the same proportion of patients attained ,50 copies/mL by week 24. Overall, 58 patients (78%) in the study were classified as non-responders at week 24 by both the TLOVR ,400 copies/mL and ,50 copies/mL ITT(E) analysis. The primary reason for non-response was virological failure, which was reported by a similar proportion of patients in each treatment group: for the ,400 copies/mL endpoint, 15 patients (63%) in the STD-FPV/RTV group, 17 patients (68%) in the HD-FPV/RTV group and 15 patients (60%) in the FPV/ LPV/RTV group. Eleven patients were classified as nonresponders for reasons other than virological failure (Table 2) .
A total of 11 patients receiving STD-FPV/RTV with evidence of protocol-defined virological failure switched to receive either HD-FPV/RTV or FPV/LPV/RTV treatment at week 12 or later. For the observed analysis, data were censored for the switch population patients from the point of switch, with a notable reduction in sample size and introduction of 'survival bias'. Observed median changes from baseline in plasma HIV-1 RNA (Table 2) were initially greater in the HD-FPV/RTV and FPV/ LPV/RTV arms, but appeared greater in the STD-FPV/RTV arm at week 24 ('survival bias'). Median changes from baseline in CD4þ cell count were positive and similar in all three treatment arms, once differential increases in the STD-FPV/RTV arm attributable to 'survival bias' were considered (Table 2) . The majority of patients (99%) did not experience disease progression during the study, and no deaths were reported. One patient progressed from a CDC Class C event to a new Class C event (Kaposi's sarcoma in a patient randomized to the FPV/LPV/RTV arm) during the treatment phase of the study.
Safety
Median exposure to the initial investigational product was 218 days [(interquartile range (IQR), 139-337 days]. Exposure was greater in patients receiving HD-FPV/RTV (276 days, IQR 155 -337 days) and FPV/LPV/RTV (229 days, IQR 138 -339 days) than in those receiving STD-FPV/RTV (149 days, IQR 112-332 days) because 10 of 24 patients in the latter group met the criteria for virological failure and were permitted (as per study design) to switch to one of the other two regimens during the course of the study. Overall, 37/74 patients (50%) reported Grade 2-4 AEs regardless of causality during the study: 9/25 patients (36%) in the STD-FPV/RTV group, 13/25 patients (52%) in the HD-FPV/RTV group and 15/24 patients (63%) in the FPV/LPV/RTV group. The organ system classes with the highest incidence of Grade 2 -4 AEs were infections and infestations [15/74 patients (20%)], followed by gastrointestinal disorders [11/74 patients (15%)]. Diarrhoea was the most common drug-related Grade 2 -4 AE, and was experienced by a higher proportion of patients in the HD-FPV/RTV (12%) and FPV/LPV/RTV (12%) arms than in the STD-FPV/RTV arm (4%). Six patients (two patients in the HD-FPV/RTV group and four patients in the FPV/LPV/RTV group) reported SAEs during the randomized phase of the study; diarrhoea was the only SAE reported in more than one patient (one patient in the HD-FPV/ RTV group and one patient in the FPV/LPV/RTV group). Only two patients reported drug-related SAEs (diarrhoea and acute renal failure) and these patients were both in the FPV/LPV/RTV group. AEs leading to discontinuation of the investigational product were reported in four patients (one patient with diarrhoea in the STD-FPV/RTV group, one patient with asthenia in the HD-FPV/RTV group and two patients in the FPV/LPV/RTV group: one with dyslipidaemia and one with diarrhoea and pyrexia). The occurrence of treatment-emergent Grade 3 or 4 increases in lipid parameters or hepatic transaminases was low (Table 3) . No treatment-emergent Grade 3 or 4 toxicities in haematology parameters occurred during the study. 5 (21) 7 (28) 5 (20) week 24 5 (21) 6 (24) 5 (20) Change from baseline HIV-1 RNA (log 10 copies/mL) by visit-ITT(E) population (observed analysis), mean (SD), n week 8 
Pharmacokinetic and pharmacodynamic analysis
Sixty-seven of all 74 patients underwent pharmacokinetic sampling. In total, 64 of 67 patients who underwent pharmacokinetic sampling provided evaluable plasma amprenavir or lopinavir C t data. Plasma amprenavir C t values were 49% higher for the HD-FPV/RTV group compared with the STD-FPV/RTV group, and were similar between the FPV/LPV/RTV and STD-FPV/RTV groups. . There was no significant correlation between log-transformed plasma amprenavir C t and the percentage of patients achieving plasma HIV-1 RNA concentrations ,400 copies/mL, or between log-transformed plasma amprenavir C t and the AAUCMB for any treatment, nor was there a relationship when the HD-FPV/RTV and STD-FPV/RTV groups were combined. Plasma amprenavir C t data are summarized by virological response for STD-FPV/RTV, HD-FPV/RTV and for these two treatments combined in Table 4 .
Viral genotyping and phenotyping and response
A summary of baseline viral genotyping and phenotyping analysis is shown in Table 5 . Although the numbers are small, a clear trend between higher baseline resistance and lower response is observed for both resistance to FPV/RTV or LPV/RTV and resistance to the background regimen. For the combined STD-FPV/RTV and HD-FPV/RTV arms, higher virological response rates were observed with higher GIQ values. Eight of 12 (66.7%) patients with a GIQ 908 and two of 23 (8.7%) patients with a GIQ ,908 achieved ,400 copies/ mL of plasma HIV-1 RNA at week 24. Similarly a higher virological response rate was observed in the top PIQ quartile (1000), with 6/10 (60%) patients achieving ,400 copies/mL of plasma HIV-1 RNA at week 24 (Table 6) . 
a One patient was randomized to the FPV/LPV/RTV group but took STD-FPV/RTV and hence is included in the STD-FPV/RTV group for the safety population.
lopinavir resistance. On-treatment genotypic changes from baseline were associated with increases in the level of resistance to fosamprenavir [median fold change (FC) increase 4.9 -9.8 for all three arms combined] and to lopinavir (median FC increase from 45 to 67 in the lopinavir arm, from 13 to 38 in the HD-FPV/RTV arm and unchanged at high resistance from 48 to 48 in the STD-FPV/RTV arm). Baseline resistance for atazanavir/RTV, indinavir/RTV and saquinavir/RTV was high at 22, 18 and 12 FC, respectively, and remained unchanged or increased slightly on-treatment to 30, 18 and 21, respectively. Overall, there was a relatively limited increase in median FC to tipranavir/RTV from 1.5 at baseline to 1.8 on-treatment. Virtual phenotypic data were not obtained for darunavir at the time of the study as such an analysis was not provided by Virco. However, baseline and on-treatment genotypes were examined for darunavir mutations (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V and L89V) and isolates were classified as resistant or intermediate with 4 or 3 of these mutations, respectively. In the STD-FPV/RTV arm, 6/20 isolates acquired on-treatment mutations overlapping with the darunavir 
Discussion
In this study of highly treatment-experienced patients, neither the investigational HD-FPV/RTV regimen nor the investigational dual-boosted FPV/LPV/RTV regimen showed demonstrable differences in virological efficacy when compared with the approved FPV/RTV dosing regimen. An early numerical difference in response rate was seen at weeks 8 and 12, and to a lesser extent at week 16; however, the differences were small, and considerable HIV-1 plasma rebound was observed such that at week 24 no difference in efficacy between the groups was observed. Thus, any potential small advantage of the higher dose or dual PI/RTV strategy over the STD-FPV/RTV arm was not durable; this may be partly explained by the suboptimal concomitant background ART used this study and/or the high rate of baseline resistance to FPV/RTV (when the updated 2006 algorithm was applied). Hence, this randomized study shows that neither strategy can play a major role in highly treatment-experienced patients with limited treatment options. Although the study was stopped prior to full enrolment, the overall results suggest that it is highly unlikely that a different conclusion would have been reached had the full complement of patients participated. Moreover, our results are consistent with a recent observational study which found that boosted double and boosted single PI regimens result in a statistically equivalent probability of virological suppression. 17 Similarly, no advantage of a dual-boosted PI strategy could be demonstrated in a recent tipranavir randomized trial. 18 Pharmacokinetic evaluation of the dual-boosted HIV-1 PI combination of FPV/LPV/RTV 1400 mg/533 mg/133 mg twice daily demonstrated plasma amprenavir C t values similar to those observed with the STD-FPV/RTV regimen, a finding that is somewhat inconsistent with previous results in healthy subjects. Plasma lopinavir C t values observed during the study were consistent with those observed in healthy subjects, and are similar to values historically observed with the standard LPV/RTV 400 mg/100 mg twice-daily regimen. 19 Another smaller study has shown exposure to amprenavir and lopinavir to be similar to that of the historical control when FPV/LPV/RTV 1400 mg/533 mg/133 mg twice daily was administered. 20 Because expected exposures to both amprenavir and lopinavir were observed in this study, their pharmacokinetics do not provide an explanation for the observed antiviral efficacy results. Overall, STD-FPV/RTV, HD-FPV/RTV and FPV/LPV/RTV were generally well tolerated by the multiple PI-experienced, HIV-infected adults in this study. There were no new safety concerns identified with any of the treatments. Grade 2 -4 clinical AEs were slightly more common in the FPV/LPV/ RTV arm than in the HD-FPV/RTV or the STD-FPV/RTV arms, but were primarily driven by previously described associations between the PIs under study and hypertriglyceridaemia and diarrhoea.
The 2004 version of the ANRS algorithm 13 was employed at study entry to determine eligibility based on susceptibility to FPV/RTV, and all except one patient in the baseline population, a major protocol violator, showed susceptibility to FPV/RTV; however, application of the 2006 ANRS algorithm 14 showed that most patients had intermediate or full resistance to fosamprenavir.
The phenotypic findings were consistent with the genotypic findings for PIs and N(t)RTIs. Most patients were treated with background N(t)RTI regimens that had at least a predicted reduced response to one or more components (93%), and the proportions of these patients with low vPSS were similar in each arm; the highest proportion was observed in the FPV/LPV/RTV arm, where 82% of patients were in this category.
As expected from such a highly ART-experienced population who had limited treatment options to optimize the background regimen, the response rate was low (20 -24% of patients with ,400 copies/mL of plasma HIV-1 RNA at week 24 across the three treatment groups), particularly when compared with that observed recently with novel antiretroviral agents of the three main classes (such as darunavir) and of new classes such as integrase inhibitors and CCR5 antagonists (approximately .60% with ,50 copies/mL of plasma HIV-1 RNA at week 24 and week 48). An analysis of response rates for subjects harbouring viruses with or ,4 mutations from the FPV/RTV ANRS 2006 mutation score 14 showed a significant difference in response between susceptible and resistant groups, consistent with the algorithm cut-off. Both the STD-FPV/RTV and HD-FPV/RTV arms showed a relationship between the FPV/RTV resistance classification and response rate, with the highest proportion of responses in the 'maximal response' (,CCO1) category and the most failures in the 'minimal response' (CCO2) category. In addition, in both the analyses of response by GIQ and PIQ there was an improved response in patients with values within the upper quartile (GIQ 908 and PIQ 1000), but no clear target (threshold) could be identified, due to the limited sample size and the relatively small number of patients with higher levels. On-treatment, major protease mutations were selected in 30% of isolates in the STD-FPV/RTV arm compared with 58% in the HD-FPV/RTV arm and 38% in the FPV/LPV/RTV arm during follow-up. The notably lower rate of on-treatment mutation selection in the STD-FPV/RTV arm than the HD-FPV/RTV might have been due to greater selection pressure in the higher dose arm (not the FPV/LPV/RTV arm as plasma exposure to amprenavir was similar to that in the STD-FPV/RTV arm) and the presence of suboptimal background support. Additional factors might have been the respective baseline resistance levels in the two groups, with the baseline resistance level higher in the STD-FPV/RTV arm, and the median duration of follow-up relatively shorter in the STD-FPV/RTV arm (17 weeks) than in the HD-FPV/RTV arm (22 weeks). Of interest, genotypic analysis showed that 1/19 isolates acquired intermediate resistance and 2/19 isolates acquired full resistance to darunavir in the HD-FPV/RTV arm compared with only 1/20 (intermediate resistance) and 0/16 in the STD-FPV/RTV and FPV/LPV/RTV arms, respectively. Although development of resistance to darunavir was infrequent (4 mutations from the DRV genotypic score), a significant number of on-treatment isolates developed fosamprenavir mutations that overlap with those of darunavir, highlighting the importance of not maintaining patients on a failing PI regimen. On an individual basis, there was a good correlation between the selection of resistance-associated mutations and changes of fosamprenavir susceptibility between baseline and on-therapy time points. Overall, the baseline virology data derived from the current study provide explanations for the relatively low antiviral efficacy observed in the three treatment arms. In addition, the on-therapy data are in accordance with the well-defined resistance profile of fosamprenavir and support the current selection of mutations included in the various algorithms for FPV/RTV susceptibility prediction.
Since TRIAD was designed, new agents in the PI class with antiviral activity against viruses with decreased susceptibility to other PIs have been approved (such as tipranavir and darunavir); these comprise new treatment options for heavily pre-treated patients such as those recruited in this study. In addition to new PIs, several investigational agents with either a superior resistance profile in the NNRTI class (TMC125) or with activity against new HIV-1 targets (entry inhibitors, integrase inhibitors) have recently been approved or submitted for approval in the EU. 21 -24 All of the above render the strategies of higher dose FPV/RTV and dual FPV/LPVRTV less relevant to current and future HIV management than at the time this study was initiated. The value of therapeutic drug monitoring for PIs in patients harbouring viruses with multiple resistance-associated mutations in PRO, as well as the value of determining the GIQ has been previously described. These approaches may be favoured over a specified dose to patients with a greater prior treatment history and intermediate resistance to a particular agent; however, the use of fully active agents available to be used in combination should always be preferred.
In conclusion, this study shows no statistical or clinical difference in efficacy between the three study arms, thus demonstrating that the use of an increased dose of FPV/RTV or a dual-boosted PI regimen (FPV/LPV/RTV) could not overcome intermediate resistance to the PIs as compared with the standard dose of FPV/RTV, particularly when co-administrated with a suboptimal background regimen. Although the regimens were relatively well tolerated, diarrhoea was more frequent in the HD-FPV/RTV and FPV/LPV/RTV arms and hypertriglyceridaemia and increased total cholesterol were more common in the FPV/LPV/RTV arm. The results do not support the use of a high-dose boosted fosamprenavir or dual-boosted PI strategy in highly treatment-experienced patients with limited treatment options and confirmed that maximal viral suppression can be best achieved with the use of two or more fully active agents as determined by baseline resistance testing and treatment history.
Dr Alan Winston and other site study staff. We also thank all patients who participated in this study.
Funding
